Arcturus Therapeutics Holdings Inc.
ARCTNASDAQHealthcare● Active
$7.12
$-0.18(-2.47%)
Market Cap$202372251
P/E Ratio—
52W High$24.17
52W Low$5.85
Arcturus Therapeutics Holdings Inc. (ARCT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARCT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $67.22M | $138.39M | $157.75M | $205.75M | $12.36M |
| Cost of Revenue | $3.02M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $64.20M | $138.39M | $157.75M | $205.75M | $12.36M |
| Gross Margin %(computed) | 95.50% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $112.21M | $195.16M | $192.13M | $147.75M | $173.76M |
| G&A Expenses | $46.08M | $52.82M | $52.87M | $46.07M | $41.45M |
| Total Operating Expenses | $139.15M | $234.06M | $235.95M | $193.58M | $215.21M |
| Operating Income | ($74.95M) | ($95.67M) | ($78.20M) | $12.18M | ($202.85M) |
| Operating Margin %(computed) | -111.51% | -69.13% | -49.58% | 5.92% | — |
| Interest Income | $10.10M | $15.20M | $17.36M | $2.58M | $0.75M |
| Interest Expense | $0.00M | $0.00M | $0.77M | $3.00M | $2.67M |
| Income Before Tax | ($65.78M) | ($80.94M) | ($27.89M) | $10.64M | ($203.67M) |
| Income Tax Expense | $0.00M | ($0.00M) | $1.83M | $1.29M | $0.00M |
| Net Income | ($65.78M) | ($80.94M) | ($29.73M) | $9.35M | ($203.67M) |
| Net Margin %(computed) | -97.86% | -58.49% | -18.84% | 4.54% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 |
| Wtd Avg Shares | 27.39M | 27.00M | 26.63M | 26.45M | 26.32M |
| EBITDA | ($71.93M) | ($77.40M) | ($24.16M) | $13.70M | ($201.66M) |
| EBITDA Margin %(computed) | -107.01% | -55.93% | -15.32% | 6.66% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Arcturus Therapeutics Holdings Inc. data
About Arcturus Therapeutics Holdings Inc. (ARCT) Income Statement
Arcturus Therapeutics Holdings Inc. (ARCT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ARCT reported revenue of $0.07B, gross profit of $0.06B (gross margin 95.50%), and net income of ($0.07B) — a net profit margin of -97.86%.
Frequently asked questions
ARCT · 4 questionsArcturus Therapeutics Holdings Inc. (ARCT) reported revenue of $0.07B for 2025, down 51.4% year-over-year.
ARCT revenueARCT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08